Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) is a Healthcare company (Biotechnology) with a market capitalization of $8.1B. The Maz Rating grades it against the other companies in its sector.
Rhythm Pharmaceuticals, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $116.61, Rhythm Pharmaceuticals, Inc. trades at 28.9x sales and 40.1x book value. Over the last twelve months it generated about $280M of revenue and a net loss of $200M. It runs a gross margin of 88.2%, an operating margin of -66.7% and a net margin of -69.0%. It shows return on equity of -83.7%, return on invested capital of -63.9% and a free cash flow yield of -1.6%. On the balance sheet: a debt-to-equity ratio of 0.02 and a current ratio of 2.78. Over the past 52 weeks the share price ranged from $74.50 to $122.20, with a beta of 2.13.
Rhythm Pharmaceuticals, Inc. does not currently pay a dividend.
22 Wall Street analyst ratings cover the stock: 22 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, including obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The firm, headquartered in Boston, Massachusetts, was established in 2008 and changed its name from Rhythm Metabolic, Inc. to Rhythm Pharmaceuticals, Inc. in October 2015.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Rhythm Pharmaceuticals, Inc. (RYTM) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 4.66% / 30% · Interest income / Revenue 3.43% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 4.66% / 33% · Receivables / Mkt Cap (36m) 0.57% / 49% · Interest income / Revenue 3.43% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 4.66% / 33.33% · Receivables / Mkt Cap (24m) 0.57% / 33.33% · Interest income / Revenue 3.43% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 0.00% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 76.6% / 33.33% · Receivables / Avg Assets (4Q) 7.75% / 33.33% · Interest income / Revenue 3.43% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 72.4% / 33.33% · (Cash+Recv) / Total Assets 81.3% / 33.33% · Interest income / Revenue 3.43% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Rhythm Pharmaceuticals, Inc. (RYTM) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. Rhythm Pharmaceuticals, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 3.43% of each dividend: Rhythm Pharmaceuticals, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.